Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877788 | 1.00 | MAPT (0.51) | MAPTKDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL4875784 | 1.00 | MAPT (0.51) | MAPTKDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL971938 | 0.87 | KDM4E (0.53) | MAPTKDM4EHSD17B10KMT2ANPC1 | |
| SCHEMBL971939 | 0.87 | KDM4E (0.53) | MAPTKDM4EHSD17B10KMT2ANPC1 | |
| SCHEMBL15000876 | 0.86 | HSD17B10 (0.47) | MAPTKDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL16925897 | 0.86 | HSD17B10 (0.47) | MAPTKDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL5550186 | 0.85 | KDM4E (0.51) | MAPTKDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL974414 | 0.84 | KDM4E (0.56) | MAPTKDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL974413 | 0.84 | KDM4E (0.56) | MAPTKDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL4875966 | 0.83 | KDM4E (0.55) | MAPTKDM4EHSD17B10KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1791835-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| WO-2006028269-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | WO | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | MAPT 430/4885KDM4E 3439/4885HSD17B10 1855/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | MAPT 320/4885KDM4E 3386/4885HSD17B10 3213/4885 |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | MAPT 1178/4885KDM4E 3463/4885HSD17B10 1895/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | MAPT 670/4885KDM4E 2818/4885HSD17B10 993/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | MAPT 320/4885KDM4E 3386/4885HSD17B10 3213/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | MAPT 1121/4885KDM4E 4108/4885HSD17B10 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.